Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label trial of intrathecal GC101 versus ongoing nusinersen in type 2 spinal muscular atrophy
CTR20251902Phase 3Active
- Sponsor
- GeneCradle
- Start
- Jun 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of nolgileucel in spinal muscular atrophy type 2 (SMA2), sponsored by GeneCradle. Started Jun 2025; status: active.
02
Drugs
nolgileucel
03
Conditions
spinal muscular atrophy type 2 (SMA2)
Beyond the preview
Go deeper on CTR20251902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251902.